by Global Immunoglobulins Market – Snapshot
The global immunoglobulins market is expected to reach a market value of about US$ 20,757 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Rise in prevalence of diseases related to neurology, immunology, hematology, and other deficiencies, rising geriatric population across the globe, leading to diseases, adoption, and awareness of effective immunoglobulins products, improving healthcare infrastructure, and rich product pipeline are expected to boost the global immunoglobulins market during the forecast period. Surge in investments by key players through collaborations, mergers, and acquisition are expected to propel the global immunoglobulins market during the forecast period. However, the high cost of treatments and severe side-effects associated with infusions are expected to hamper the immunoglobulins market. Niche rare disease segment with limited product availability is likely to fuel the market.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111969
The global immunoglobulins market has been segmented based on applications, route of administration, and end-user. In terms of applications, the global market has been classified into neurology, immunology, hematology, and others. The neurology segment dominates the global immunoglobulins market, in terms of value, owing to its indication prevalence. This immunology segment is expected to expand at a significant CAGR owing to higher prevalence of idiopathic thrombocytopenic purpura (ITP), primary immunodeficiency, and other indications. Based on route of administration, the global immunoglobulins market has been divided into intravenous, subcutaneous, and intramuscular. The intravenous segment held a major share of the market in 2017. It is expected to maintain its leading position, in terms of market share, during the forecast period owing to its rapid onset of action. However, benefits of subcutaneous over intravenous are presently slowly adaptable in the market and hence, the subcutaneous segment is projected to expand at a notable CAGR during the forecast period.
In terms of end-user, the global immunoglobulins market has been segregated into hospital, clinic, and homecare. The hospital segment held a major share of the market in 2017, followed by clinic and homecare segments, owing to the acceptance of advanced treatment requiring hospitalization. The homecare segment is projected to expand at a considerable CAGR during the forecast period owing to easy administration of infusions at home, supporting personal care, as well as it saves the cost of treatment. In developing countries, the medical care isn’t funded completely by the government; hence, the rising adoption of homecare is advantageous to patients. Preference of subcutaneous products is also driving the homecare segment
In terms of geography, the global immunoglobulins market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global immunoglobulins market owing to major acceptance of intravenous infusions, increasing plasma yield, healthcare investments by the government, and presence of major players in the region. According to the Immune Deficiency Foundation (IDF), there are more than 5 million undiagnosed cases in the U.S., which in turn is driving innovative therapeutic treatments and huge investments. Rising incidence of neurological, autoimmune disorders is boosting the demand for effective treatment, which in turn is a major factor driving the market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to improving health care infrastructure, rising investments in research and development, increasing disposable income, awareness about IVIG infusions in countries, such as China and India, and increasing acceptance of SCIG infusions in the region. IVIG accounts for a prominent share of the plasma market in China. Furthermore, the prevalence of CIDP, ITP diseases is anticipated to further boost the market in Asia Pacific in the near future.
Major players operating in the global immunoglobulins market include Shire, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A., Octapharma, China Biologic Products Holdings Inc, Biotest AG, Sanquin, and LFB SA. Key players are focusing on geographic expansion through acquisitions and collaborations to enhance their footprint in the global immunoglobulins market. Furthermore, companies are investing in pipeline products for building strong product portfolio.
IVIg Usage in Treating Severe COVID-19 Cases will bring Good Growth Opportunities for the Immunoglobulins Market
The immunoglobulins market is extrapolated to gain intensive growth opportunities owing to the increasing cases of immunodeficiency. The changing lifestyle habits and hectic work schedules have led to problems related to immunodeficiency. Thus, this aspect will bring good growth opportunities for the immunoglobulins market during the forecast period of 2018-2026.
Immunoglobulins are glycoproteins created in response to an immunogen by plasma cells and act as antibodies. They generally bind to antigenic determinants and eliminate the threat of infections. Hence, all these aspects bring exponential growth for the immunoglobulins market.
The booming geriatric population and a rise in the number of hemophilic patients will serve as a vital growth generator for the immunoglobulins market. The popularity of immunoglobulin therapy as the preferred treatment for immunodeficiency and other rare neurological diseases may invite exponential growth for the immunoglobulins market. The escalating focus on immune disorder diagnosis will serve as a prominent growth factor. Quick regulatory approvals are also helping in boosting the growth prospects of the immunoglobulins market.
Research and development activities are playing a crucial role in the growth of the immunoglobulins market. The players in the immunoglobulins market focus on these activities for discovering unique insights. The insights assist in boosting the revenues of the players in the immunoglobulins market, ultimately adding extra stars of growth.
The COVID-19 outbreak is one of the worst pandemics the world has ever faced. The rapid transmission rate and the high fatality rate have left many scientists and researchers searching for a good treatment option. Many options have been discovered by researchers and scientists. The utilization of immunoglobulins is one of them. The utilization of Intravenous immunoglobulin (IVIg) for treating serious COVID-19 patients is being considered by many scientists and researchers. A recent study also showcased the efficacy of IVIg in treating COVID-19 patients. Thus, this aspect can bring great growth opportunities for the immunoglobulins market.
The global immunoglobulins market has been segmented as below:
by Applications
- Neurology
- Immunology
- Hematology
- Others
by Route Of Administration
- Intravenous
- Subcutaneous
- Intramuscular
by End-user
- Hospital
- Clinic
- Homecare
by Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- GCC Countries
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111969/2900
